| 1 |
Conway, K.A., Harper, J.D., and Lansbury, P.T. (1998). Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med 4, 1318-1320.
DOI
ScienceOn
|
| 2 |
Iwatsubo, T. (2007). Pathological biochemistry of alpha-synucleinopathy. Neuropathology 27, 474-478.
DOI
|
| 3 |
Olzscha, H., Schermann, S.M., Woerner, A.C., Pinkert, S., Hecht, M.H., Tartaglia, G.G., Vendruscolo, M., Hayer-Hartl, M., Hartl, F.U., and Vabulas, R.M. (2011). Amyloid-like aggregates sequester numerous metastable proteins with essential cellular functions. Cell 144, 67-78.
DOI
|
| 4 |
Jellinger, K.A. (2003). Neuropathological spectrum of synucleinopathies. Mov Disord 18 Suppl 6, S2-12.
|
| 5 |
Wakabayashi, K., Tanji, K., Mori, F., and Takahashi, H. (2007). The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates. Neuropathology 27, 494-506.
DOI
|
| 6 |
Cabeza-Arvelaiz, Y., Fleming, S.M., Richter, F., Masliah, E., Chesselet, M.F., and Schiestl, R.H. (2011). Analysis of striatal transcriptome in mice overexpressing human wild-type alpha-synuclein supports synaptic dysfunction and suggests mechanisms of neuroprotection for striatal neurons. Mol Neurodegener 6, 83.
DOI
|
| 7 |
Speciale, S.G. (2002). MPTP: insights into parkinsonian neurodegeneration. Neurotoxicol Teratol 24, 607-620.
DOI
|
| 8 |
Mandir, A.S., Przedborski, S., Jackson-Lewis, V., Wang, Z.Q., Simbulan- Rosenthal, C.M., Smulson, M.E., Hoffman, B.E., Guastella, D.B., Dawson, V.L., and Dawson, T.M. (1999). Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. Proc Natl Acad Sci U S A 96, 5774- 5779.
DOI
ScienceOn
|
| 9 |
Pallanck, L., and Greenamyre, J.T. (2006). Neurodegenerative disease: pink, parkin and the brain. Nature 441, 1058.
DOI
|
| 10 |
Doherty, M.K., Hammond, D.E., Clague, M.J., Gaskell, S.J., and Beynon, R.J. (2009). Turnover of the human proteome: determination of protein intracellular stability by dynamic SILAC. J Proteome Res 8, 104-112.
DOI
|
| 11 |
West, A.B., Moore, D.J., Biskup, S., Bugayenko, A., Smith, W.W., Ross, C.A., Dawson, V.L., and Dawson, T.M. (2005). Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A 102, 16842-16847.
DOI
ScienceOn
|
| 12 |
Smith, W.W., Pei, Z., Jiang, H., Dawson, V.L., Dawson, T.M., and Ross, C.A. (2006). Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci 9, 1231-1233.
DOI
ScienceOn
|
| 13 |
Lee, B.D., Shin, J.H., VanKampen, J., Petrucelli, L., West, A.B., Ko, H.S., Lee, Y.I., Maguire-Zeiss, K.A., Bowers, W.J., Federoff, H.J., et al. (2010). Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat Med 16, 998-1000.
DOI
|
| 14 |
Lin, X., Parisiadou, L., Gu, X.L., Wang, L., Shim, H., Sun, L., Xie, C., Long, C.X., Yang, W.J., Ding, J., et al. (2009). Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson'sdisease- related mutant alpha-synuclein. Neuron 64, 807-827.
DOI
|
| 15 |
Tong, Y., and Shen, J. (2009). Alpha-synuclein and LRRK2: partners in crime. Neuron 64, 771-773.
DOI
|
| 16 |
Gehrke, S., Imai, Y., Sokol, N., and Lu, B. (2010). Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression. Nature 466, 637-641.
DOI
ScienceOn
|
| 17 |
Pridgeon, J.W., Olzmann, J.A., Chin, L.S., and Li, L. (2007). PINK1 protects against oxidative stress by phosphorylating mitochondrial chaperone TRAP1. PLoS Biol 5, e172.
DOI
|
| 18 |
Sonntag, K.C., Simantov, R., and Isacson, O. (2005). Stem cells may reshape the prospect of Parkinson's disease therapy. Brain Res Mol Brain Res 134, 34-51.
DOI
|
| 19 |
Valjent, E., Bertran-Gonzalez, J., Herve, D., Fisone, G., and Girault, J.A. (2009). Looking BAC at striatal signaling: cell-specific analysis in new transgenic mice. Trends Neurosci 32, 538-547.
DOI
|
| 20 |
Park, C.H., Minn, Y.K., Lee, J.Y., Choi, D.H., Chang, M.Y., Shim, J.W., Ko, J.Y., Koh, H.C., Kang, M.J., Kang, J.S., et al. (2005). In vitro and in vivo analyses of human embryonic stem cell-derived dopamine neurons. J Neurochem 92, 1265-1276.
DOI
|
| 21 |
Takahashi, J. (2006). Stem cell therapy for Parkinson's disease. Ernst Schering Res Found Workshop, 60, 229-244.
DOI
|
| 22 |
Gunaseeli, I., Doss, M.X., Antzelevitch, C., Hescheler, J., and Sachinidis, A. (2010). Induced pluripotent stem cells as a model for accelerated patient- and disease-specific drug discovery. Curr Med Chem 17, 759-766.
DOI
|
| 23 |
Wilmut, I., Schnieke, A.E., McWhir, J., Kind, A.J., and Campbell, K.H. (1997). Viable offspring derived from fetal and adult mammalian cells. Nature 385, 810-813.
DOI
ScienceOn
|
| 24 |
Egli, D., and Eggan, K. (2010). Recipient cell nuclear factors are required for reprogramming by nuclear transfer. Development 137, 1953- 1963.
DOI
|
| 25 |
Yamanaka, S. (2008). Induction of pluripotent stem cells from mouse fibroblasts by four transcription factors. Cell Prolif 41 Suppl 1, 51-56.
|
| 26 |
Lo, B., and Parham, L. (2009). Ethical issues in stem cell research. Endocr Rev 30, 204-213.
DOI
|
| 27 |
Linazasoro, G. (2003). Stem cells: solution to the problem of transplants in Parkinson's disease? Neurologia 18, 74-100.
|
| 28 |
Lang, A.E., and Lozano, A.M. (1998). Parkinson's disease. Second of two parts. N Engl J Med 339, 1130-1143.
DOI
|
| 29 |
Moore, D.J., West, A.B., Dawson, V.L., and Dawson, T.M. (2005). Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci 28, 57-87.
DOI
ScienceOn
|
| 30 |
Lang, A.E., and Lozano, A.M. (1998). Parkinson's disease. First of two parts. N Engl J Med 339, 1044-1053.
DOI
ScienceOn
|
| 31 |
Dawson, T.M., and Dawson, V.L. (2003). Rare genetic mutations shed light on the pathogenesis of Parkinson disease. J Clin Invest 111, 145-151.
DOI
|
| 32 |
Cookson, M.R. (2003). Parkin's substrates and the pathways leading to neuronal damage. Neuromolecular Med 3, 1-13.
DOI
|
| 33 |
Cookson, M.R., Dauer, W., Dawson, T., Fon, E.A., Guo, M., and Shen, J. (2007). The roles of kinases in familial Parkinson's disease. J Neurosci 27, 11865-11868.
DOI
|
| 34 |
Chu, C.T. (2010). Tickled PINK1: mitochondrial homeostasis and autophagy in recessive Parkinsonism. Biochim Biophys Acta 1802, 20-28.
DOI
|
| 35 |
Imai, Y., Soda, M., and Takahashi, R. (2000). Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J Biol Chem 275, 35661-35664.
DOI
|
| 36 |
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., and Shimizu, N. (1998). Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392, 605-608.
DOI
ScienceOn
|
| 37 |
Ko, H.S., von Coelln, R., Sriram, S.R., Kim, S.W., Chung, K.K., Pletnikova, O., Troncoso, J., Johnson, B., Saffary, R., Goh, E.L., et al. (2005). Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death. J Neurosci 25, 7968-7978.
DOI
|
| 38 |
Kwok, J.B. (2010). Role of epigenetics in Alzheimer's and Parkinson's disease. Epigenomics 2, 671-682.
DOI
|
| 39 |
Park, J., Lee, S.B., Lee, S., Kim, Y., Song, S., Kim, S., Bae, E., Kim, J., Shong, M., Kim, J.M., et al. (2006). Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 441, 1157-1161.
DOI
ScienceOn
|
| 40 |
Tan, J.M., and Dawson, T.M. (2006). Parkin blushed by PINK1. Neuron 50, 527-529.
DOI
|
| 41 |
Habibi, E., Masoudi-Nejad, A., Abdolmaleky, H.M., and Haggarty, S.J. (2011). Emerging roles of epigenetic mechanisms in Parkinson's disease. Funct Integr Genomics 11, 523-537.
DOI
|
| 42 |
Marques, S.C., Oliveira, C.R., Pereira, C.M., and Outeiro, T.F. (2011). Epigenetics in neurodegeneration: a new layer of complexity. Prog Neuropsychopharmacol Biol Psychiatry 35, 348-355.
DOI
|
| 43 |
Kaut, O., Schmitt, I., and Wullner, U. (2012). Genome-scale methylation analysis of Parkinson's disease patients' brains reveals DNA hypomethylation and increased mRNA expression of cytochrome P450 2E1. Neurogenetics 13, 87-91.
DOI
|
| 44 |
Jowaed, A., Schmitt, I., Kaut, O., and Wullner, U. (2010). Methylation regulates alpha-synuclein expression and is decreased in Parkinson's disease patients' brains. J Neurosci 30, 6355-6359.
DOI
|
| 45 |
Xu, K., Dai, X.L., Huang, H.C., and Jiang, Z.F. (2011). Targeting HDACs: a promising therapy for Alzheimer's disease. Oxid Med Cell Longev 2011, 143269.
|
| 46 |
Brochier, C., Gaillard, M.C., Diguet, E., Caudy, N., Dossat, C., Segurens, B., Wincker, P., Roze, E., Caboche, J., Hantraye, P., et al. (2008). Quantitative gene expression profiling of mouse brain regions reveals differential transcripts conserved in human and affected in disease models. Physiol Genomics 33, 170-179.
DOI
|
| 47 |
Lin, W., and Kang, U.J. (2008). Characterization of PINK1 processing, stability, and subcellular localization. J Neurochem 106, 464-474.
DOI
|
| 48 |
Vives-Bauza, C., Zhou, C., Huang, Y., Cui, M., de Vries, R.L., Kim, J., May, J., Tocilescu, M.A., Liu, W., Ko, H.S., et al. (2010). PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. Proc Natl Acad Sci U S A 107, 378-383.
DOI
|
| 49 |
Whitworth, A.J., and Pallanck, L.J. (2009). The PINK1/Parkin pathway: a mitochondrial quality control system? J Bioenerg Biomembr 41, 499-503.
DOI
|
| 50 |
Jin, S.M., Lazarou, M., Wang, C., Kane, L.A., Narendra, D.P., and Youle, R.J. (2010). Mitochondrial membrane potential regulates PINK1 import and proteolytic destabilization by PARL. J Cell Biol 191, 933-942.
DOI
|
| 51 |
Moriwaki, Y., Kim, Y.J., Ido, Y., Misawa, H., Kawashima, K., Endo, S., and Takahashi, R. (2008). L347P PINK1 mutant that fails to bind to Hsp90/ Cdc37 chaperones is rapidly degraded in a proteasome-dependent manner. Neurosci Res 61, 43-48.
DOI
|
| 52 |
Ong, S.E., Blagoev, B., Kratchmarova, I., Kristensen, D.B., Steen, H., Pandey, A., and Mann, M. (2002). Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics 1, 376-386.
DOI
|
| 53 |
Krijgsveld, J., Ketting, R.F., Mahmoudi, T., Johansen, J., Artal-Sanz, M., Verrijzer, C.P., Plasterk, R.H., and Heck, A.J. (2003). Metabolic labeling of C. elegans and D. melanogaster for quantitative proteomics. Nat Biotechnol 21, 927-931.
DOI
|
| 54 |
Kruger, M., Moser, M., Ussar, S., Thievessen, I., Luber, C.A., Forner, F., Schmidt, S., Zanivan, S., Fassler, R., and Mann, M. (2008). SILAC mouse for quantitative proteomics uncovers kindlin-3 as an essential factor for red blood cell function. Cell 134, 353-364.
DOI
|
| 55 |
Ko, H.S., Lee, Y., Shin, J.H., Karuppagounder, S.S., Gadad, B.S., Koleske, A.J., Pletnikova, O., Troncoso, J.C., Dawson, V.L., and Dawson, T.M. (2010). Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function. Proc Natl Acad Sci U S A 107, 16691-16696.
DOI
ScienceOn
|
| 56 |
Shin, J.H., Ko, H.S., Kang, H., Lee, Y., Lee, Y.I., Pletinkova, O., Troconso, J.C., Dawson, V.L., and Dawson, T.M. (2011). PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson's disease. Cell 144, 689-702.
DOI
|
| 57 |
da Costa, C.A., Sunyach, C., Giaime, E., West, A., Corti, O., Brice, A., Safe, S., Abou-Sleiman, P.M., Wood, N.W., Takahashi, H., et al. (2009). Transcriptional repression of p53 by parkin and impairment by mutations associated with autosomal recessive juvenile Parkinson's disease. Nat Cell Biol 11, 1370-1375.
DOI
|
| 58 |
Chung, K.K., Thomas, B., Li, X., Pletnikova, O., Troncoso, J.C., Marsh, L., Dawson, V.L., and Dawson, T.M. (2004). S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. Science 304, 1328-1331.
DOI
ScienceOn
|
| 59 |
Imam, S.Z., Zhou, Q., Yamamoto, A., Valente, A.J., Ali, S.F., Bains, M., Roberts, J.L., Kahle, P.J., Clark, R.A., and Li, S. (2011). Novel regulation of parkin function through c-Abl-mediated tyrosine phosphorylation: implications for Parkinson's disease. J Neurosci 31, 157-163.
DOI
ScienceOn
|
| 60 |
Liu, J., Chung, H.J., Vogt, M., Jin, Y., Malide, D., He, L., Dundr, M., and Levens, D. (2011). JTV1 co-activates FBP to induce USP29 transcription and stabilize p53 in response to oxidative stress. EMBO J 30, 846-858.
DOI
|
| 61 |
Rothfuss, O., Fischer, H., Hasegawa, T., Maisel, M., Leitner, P., Miesel, F., Sharma, M., Bornemann, A., Berg, D., Gasser, T., et al. (2009). Parkin protects mitochondrial genome integrity and supports mitochondrial DNA repair. Hum Mol Genet 18, 3832-3850.
DOI
|
| 62 |
Forno, L.S. (1987). The Lewy body in Parkinson's disease. Adv Neurol 45, 35-43.
|
| 63 |
Seo, J., and Lee, K.J. (2004). Post-translational modifications and their biological functions: proteomic analysis and systematic approaches. J Biochem Mol Biol 37, 35-44.
DOI
ScienceOn
|
| 64 |
Wang, Z., Gerstein, M., and Snyder, M. (2009). RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet 10, 57-63.
DOI
|
| 65 |
Duke, D.C., Moran, L.B., Kalaitzakis, M.E., Deprez, M., Dexter, D.T., Pearce, R.K., and Graeber, M.B. (2006). Transcriptome analysis reveals link between proteasomal and mitochondrial pathways in Parkinson's disease. Neurogenetics 7, 139-148.
DOI
|
| 66 |
Gillardon, F., Mack, M., Rist, W., Schnack, C., Lenter, M., Hildebrandt, T., and Hengerer, B. (2008). MicroRNA and proteome expression profiling in early-symptomatic alpha-synuclein(A30P)-transgenic mice. Proteomics Clin Appl 2, 697-705.
DOI
|
| 67 |
Moore, D.J. (2006). Parkin: a multifaceted ubiquitin ligase. Biochem Soc Trans 34, 749-753.
DOI
|
| 68 |
Vasilescu, J., Smith, J.C., Ethier, M., and Figeys, D. (2005). Proteomic analysis of ubiquitinated proteins from human MCF-7 breast cancer cells by immunoaffinity purification and mass spectrometry. J Proteome Res 4, 2192-2200.
DOI
|
| 69 |
Dawson, T.M. (2006). Parkin and defective ubiquitination in Parkinson's disease. J Neural Transm Suppl, 209-213.
|
| 70 |
Choi, J.W., Um, J.Y., Kundu, J.K., Surh, Y.J., and Kim, S. (2009). Multidirectional tumor-suppressive activity of AIMP2/p38 and the enhanced susceptibility of AIMP2 heterozygous mice to carcinogenesis. Carcinogenesis 30, 1638-1644.
DOI
|
| 71 |
Hwang, S.I., Lundgren, D.H., Mayya, V., Rezaul, K., Cowan, A.E., Eng, J.K., and Han, D.K. (2006). Systematic characterization of nuclear proteome during apoptosis: a quantitative proteomic study by differential extraction and stable isotope labeling. Mol Cell Proteomics 5, 1131-1145.
DOI
|
| 72 |
Gibson, B.W. (2005). The human mitochondrial proteome: oxidative stress, protein modifications and oxidative phosphorylation. Int J Biochem Cell Biol 37, 927-934.
DOI
|
| 73 |
de Godoy, L.M., Olsen, J.V., de Souza, G.A., Li, G., Mortensen, P., and Mann, M. (2006). Status of complete proteome analysis by mass spectrometry: SILAC labeled yeast as a model system. Genome Biol 7, R50.
|
| 74 |
Seibler, P., Graziotto, J., Jeong, H., Simunovic, F., Klein, C., and Krainc, D. (2011). Mitochondrial Parkin recruitment is impaired in neurons derived from mutant PINK1 induced pluripotent stem cells. J Neurosci 31, 5970-5976.
DOI
|
| 75 |
Basso, M., Giraudo, S., Corpillo, D., Bergamasco, B., Lopiano, L., and Fasano, M. (2004). Proteome analysis of human substantia nigra in Parkinson's disease. Proteomics 4, 3943-3952.
DOI
|
| 76 |
Lu, L., Neff, F., Alvarez-Fischer, D., Henze, C., Xie, Y., Oertel, W.H., Schlegel, J., and Hartmann, A. (2005). Gene expression profiling of Lewy body-bearing neurons in Parkinson's disease. Exp Neurol 195, 27-39.
DOI
|
| 77 |
Greene, J.G., Dingledine, R., and Greenamyre, J.T. (2010). Neuron-selective changes in RNA transcripts related to energy metabolism in toxic models of parkinsonism in rodents. Neurobiol Dis 38, 476-481.
DOI
|
| 78 |
Stephenson, D., Ramirez, A., Long, J., Barrezueta, N., Hajos-Korcsok, E., Matherne, C., Gallagher, D., Ryan, A., Ochoa, R., Menniti, F., et al. (2007). Quantification of MPTP-induced dopaminergic neurodegeneration in the mouse substantia nigra by laser capture microdissection. J Neurosci Methods 159, 291-299.
DOI
|
| 79 |
Heiman, M., Schaefer, A., Gong, S., Peterson, J.D., Day, M., Ramsey, K.E., Suarez-Farinas, M., Schwarz, C., Stephan, D.A., Surmeier, D.J., et al. (2008). A translational profiling approach for the molecular characterization of CNS cell types. Cell 135, 738-748.
DOI
|
| 80 |
Fukuda, H., Takahashi, J., Watanabe, K., Hayashi, H., Morizane, A., Koyanagi, M., Sasai, Y., and Hashimoto, N. (2006). Fluorescence-activated cell sorting-based purification of embryonic stem cell-derived neural precursors averts tumor formation after transplantation. Stem Cells 24, 763-771.
DOI
ScienceOn
|
| 81 |
Fusaki, N., Ban, H., Nishiyama, A., Saeki, K., and Hasegawa, M. (2009). Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proc Jpn Acad Ser B Phys Biol Sci 85, 348-362.
DOI
|
| 82 |
Kriks, S., Shim, J.W., Piao, J., Ganat, Y.M., Wakeman, D.R., Xie, Z., Carrillo- Reid, L., Auyeung, G., Antonacci, C., Buch, A., et al. (2011). Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature 480, 547-551.
|
| 83 |
Sanchez-Danes, A., Consiglio, A., Richaud, Y., Rodriguez-Piza, I., Dehay, B., Edel, M., Bove, J., Memo, M., Vila, M., Raya, A., et al. (2012). Efficient generation of A9 midbrain dopaminergic neurons by lentiviral delivery of LMX1A in human embryonic stem cells and induced pluripotent stem cells. Hum Gene Ther 23, 56-69.
DOI
|
| 84 |
Hedlund, E., Pruszak, J., Ferree, A., Vinuela, A., Hong, S., Isacson, O., and Kim, K.S. (2007). Selection of embryonic stem cell-derived enhanced green fluorescent protein-positive dopamine neurons using the tyrosine hydroxylase promoter is confounded by reporter gene expression in immature cell populations. Stem Cells 25, 1126-1135.
DOI
|
| 85 |
Pruszak, J., Just, L., Isacson, O., and Nikkhah, G. (2009). Isolation and culture of ventral mesencephalic precursor cells and dopaminergic neurons from rodent brains. Curr Protoc Stem Cell Biol Chapter 2, Unit 2D 5.
|
| 86 |
Pruszak, J., Sonntag, K.C., Aung, M.H., Sanchez-Pernaute, R., and Isacson, O. (2007). Markers and methods for cell sorting of human embryonic stem cell-derived neural cell populations. Stem Cells 25, 2257-2268.
DOI
|
| 87 |
Jiang, H., Ren, Y., Yuen, E.Y., Zhong, P., Ghaedi, M., Hu, Z., Azabdaftari, G., Nakaso, K., Yan, Z., and Feng, J. (2012). Parkin controls dopamine utilization in human midbrain dopaminergic neurons derived from induced pluripotent stem cells. Nat Commun 3, 668.
DOI
|
| 88 |
Placantonakis, D.G., Tomishima, M.J., Lafaille, F., Desbordes, S.C., Jia, F., Socci, N.D., Viale, A., Lee, H., Harrison, N., Tabar, V., et al. (2009). BAC transgenesis in human embryonic stem cells as a novel tool to define the human neural lineage. Stem Cells 27, 521-532.
DOI
|
| 89 |
Byers, B., Cord, B., Nguyen, H.N., Schule, B., Fenno, L., Lee, P.C., Deisseroth, K., Langston, J.W., Pera, R.R., and Palmer, T.D. (2011). SNCA triplication Parkinson's patient's iPSC-derived DA neurons accumulate alpha-synuclein and are susceptible to oxidative stress. PLoS One 6, e26159.
DOI
|
| 90 |
Nguyen, H.N., Byers, B., Cord, B., Shcheglovitov, A., Byrne, J., Gujar, P., Kee, K., Schule, B., Dolmetsch, R.E., Langston, W., et al. (2011). LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell 8, 267-280.
DOI
|
| 91 |
Soldner, F., Laganiere, J., Cheng, A.W., Hockemeyer, D., Gao, Q., Alagappan, R., Khurana, V., Golbe, L.I., Myers, R.H., Lindquist, S., et al. (2011). Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell 146, 318-331.
DOI
|
webmaster
